MarketResearch.biz delivers in-depth insights in its upcoming report titled “Global Primary Progressive Multiple Sclerosis Market Trends, Applications, Analysis, Growth, and Forecast: 2017 to 2026”. The global primary progressive multiple sclerosis market is estimated to register a CAGR of X.X% in terms of value during forecast period 2017–2026. The report offers in-depth insights, revenue details, and other vital information regarding the global primary progressive multiple sclerosis market, and the various trends, drivers, restraints, opportunities, and threats in the target market till 2026. The report offers insightful and detailed information regarding the various key players operating in the global primary progressive multiple sclerosis market, their financials, supply chain trends, technological innovations, key developments, apart from future strategies, acquisitions & mergers, and market footprint. The global primary progressive multiple sclerosis market report has been segmented on the basis of types of treatment, location of treatment, and region.
Multiple sclerosis (MS) also referred to as disseminated sclerosis, is an inflammatory disease of the nervous system. It is mainly characterized by the disruption of the nerve cells of the spinal cord and the brain of an affected individual, which results in the loss of ability to communicate along with various other physical, mental as well as psychiatric problems. Primary progressive multiple sclerosis (PPMS) is a type of MS in which the neurological functioning steadily deteriorates with no distinct relapses or fixed period of remissions. Only 10% - 15% of the total multiple sclerosis(MS) patients are diagnosed with primary progressive multiple sclerosis (PPMS). The rate of progression of PPMS may differ from person to person as well as over time. Signs of temporary improvement may be visible but the disease progression remains consistent.
High prevalence of neurological disorders and demand for advanced therapeutics for the treatment of primary progressive multiple sclerosis (PPMS) are key drivers driving the growth of global primary progressive multiple sclerosis market. Increasing awareness among general population and availability of affordable medication for the treatment of PPMS are other major factors responsible for growth of the global primary progressive multiple sclerosis (PPMS) market.
However, inaccurate methods for diagnosis and treatment of primary progressive multiple sclerosis (PPMS), is a major restraint for the growth of global primary progressive multiple sclerosis (PPMS) market. Awareness among the general population and unavailability of proper treatment in remote areas are some restraining factors for the growth of primary progressive multiple sclerosis market.
As incidence of primary progressive multiple sclerosis is growing, demand for advanced therapeutics for the treatment of PPMS is at an all-time high. This untapped demand from emerging economies provides an opportunity for growth of the global primary progressive multiple sclerosis(PPMS) market.
North America and Europe are expected to dominate the global primary progressive sclerosis(PPMS) market, owing to high demand of therapeutic drugs and effective treatment of PPMS in these geographies. According to multiple sclerosis portal, 0.5 million people are affected with multiple sclerosis in Europe and 0.4 million people affected population is present in the United States. Asia Pacific is expected to grow at a much faster pace over the forecast period, due to rising awareness among people and growth in emerging economics like India and China
Global primary progressive multiple sclerosis market segmentation by types of treatment:
- Magnetic Resonance Imaging (MRI) Scans
- Simple electrical stimulation tests
- Lumbar puncture
Global primary progressive multiple sclerosis market segmentation by location of treatment:
- Hospital testing
- Commercial/private hospitals
- Public health hospitals
- Symptomatic diagnostic testing with medications
- Home Treatment
- Managing symptoms
- Healthy living
Global primary progressive multiple sclerosis market segmentation by region:
- North America
- Asia Pacific
- Latin America
- Middle East & Africa
Particular Scope Region
- North America
- Rest of Europe
- Asia Pacific
- Rest of Asia Pacific
- Latin America
- Rest of Latin America
- Middle East and Africa
- South Africa
- Rest of Middle East and Africa
Actual Year 2016 Estimated Year 2017 Forecast Period 2017–2026 Revenue in US$
- Hoffmann-La Roche Ltd.
- Innate Immunotherapeutics Ltd.
- Teva Pharmaceutical Industries
- Genzyme Corporation
- Glialogix, Inc.
- Kyorin Pharmaceutical Co., Ltd.
- MedDay SA
- Santhera Pharmaceuticals Holding AG
- AB Science
Request for TOC
Request for Customization
Don't just take our word. We are trusted by these great companies!